223 related articles for article (PubMed ID: 20377918)
1. Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia.
Wang L; Zhu K; Zha X; Chen S; Yang L; Chen S; Li Y
J Hematol Oncol; 2010 Apr; 3():14. PubMed ID: 20377918
[TBL] [Abstract][Full Text] [Related]
2. T cell receptor Vbeta repertoire usage and clonal expansion of T cells in chronic myelogenous leukemia.
Li YQ; Yang LJ; Chen SH; Zhang YP; Zhang XL; Luo GX
Chin Med J (Engl); 2004 Jun; 117(6):840-3. PubMed ID: 15198883
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
[TBL] [Abstract][Full Text] [Related]
4. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
5. [The distribution feature of TCR Vbeta repertoire in peripheral blood T cells from patients with Ph(+) and Ph(-) CML].
Zhang YP; Li YQ; Chen SH; Yang LJ; Li RF; Xu MH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Apr; 10(2):122-5. PubMed ID: 12513813
[TBL] [Abstract][Full Text] [Related]
6. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Bumm T; Müller C; Al-Ali HK; Krohn K; Shepherd P; Schmidt E; Leiblein S; Franke C; Hennig E; Friedrich T; Krahl R; Niederwieser D; Deininger MW
Blood; 2003 Mar; 101(5):1941-9. PubMed ID: 12411298
[TBL] [Abstract][Full Text] [Related]
7. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
8. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Braziel RM; Launder TM; Druker BJ; Olson SB; Magenis RE; Mauro MJ; Sawyers CL; Paquette RL; O'Dwyer ME
Blood; 2002 Jul; 100(2):435-41. PubMed ID: 12091333
[TBL] [Abstract][Full Text] [Related]
9. The TCR Vbeta repertoire usage of T-cells from cord blood induced by chronic myelogenous leukemia associated antigen.
Li Y; Yang L; Chen S; Zhang Y; Wu X
Hematology; 2005 Oct; 10(5):387-92. PubMed ID: 16273727
[TBL] [Abstract][Full Text] [Related]
10. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
11. [Peripheral blood naive T cell level and its T cell receptor Vbeta repertoire usage profile in patients with chronic myelogenous leukemia].
Geng SX; Li YQ; Chen SH; Yang LJ; Yin QS; Wu XL; Zhang XL
Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):413-6. PubMed ID: 16251024
[TBL] [Abstract][Full Text] [Related]
12. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
O'Dwyer ME; Gatter KM; Loriaux M; Druker BJ; Olson SB; Magenis RE; Lawce H; Mauro MJ; Maziarz RT; Braziel RM
Leukemia; 2003 Mar; 17(3):481-7. PubMed ID: 12646934
[TBL] [Abstract][Full Text] [Related]
13. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
Terre C; Eclache V; Rousselot P; Imbert M; Charrin C; Gervais C; Mozziconacci MJ; Maarek O; Mossafa H; Auger N; Dastugue N; Talmant P; Van den Akker J; Leonard C; N'Guyen Khac F; Mugneret F; Viguié F; Lafage-Pochitaloff M; Bastie JN; Roux GL; Nicolini F; Maloisel F; Vey N; Laurent G; Recher C; Vigier M; Yacouben Y; Giraudier S; Vernant JP; Salles B; Roussi J; Castaigne S; Leymarie V; Flandrin G; Lessard M;
Leukemia; 2004 Aug; 18(8):1340-6. PubMed ID: 15190256
[TBL] [Abstract][Full Text] [Related]
14. Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
Herens C; Baron F; Croisiau C; Tassin F; Bours V
Cancer Genet Cytogenet; 2003 Nov; 147(1):78-80. PubMed ID: 14580776
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the CDR3 structure of the Vβ21 T cell clone in patients with P210(BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia.
Zha X; Chen S; Yang L; Li B; Chen Y; Yan X; Li Y
Hum Immunol; 2011 Oct; 72(10):798-804. PubMed ID: 21820025
[TBL] [Abstract][Full Text] [Related]
16. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
Kolb EA; Pan Q; Ladanyi M; Steinherz PG
Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
[TBL] [Abstract][Full Text] [Related]
18. Extensive cytogenetic studies of clonality following interferon-alpha therapy in chronic myeloid leukemia occurring in monosomic cells in a patient with Turner syndrome mosaic.
Takeshita A; Shinjo K; Yamashita M; Fujisawa S; Naito K; Ohnishi K; Takahashi K; Matsui H; Ohno R
Leukemia; 1999 Nov; 13(11):1749-53. PubMed ID: 10557048
[TBL] [Abstract][Full Text] [Related]
19. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
Alimena G; Breccia M; Luciano L; Quarantelli F; Diverio D; Izzo B; De Angelis B; Mancini M; Latagliata R; Carmosino I; Nanni M; Picardi M; Rotoli B; Mandelli F; Pane F
Leuk Res; 2008 Feb; 32(2):255-61. PubMed ID: 17692911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
